NASDAQ:LMDX LumiraDx (LMDX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.0076▼$0.016052-Week Range N/AVolume132.24 million shsAverage Volume56.75 million shsMarket Capitalization$5.10 millionP/E RatioN/ADividend YieldN/APrice Target$0.80 Stock AnalysisStock Analysis Get LumiraDx alerts: Email Address Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About LumiraDx Stock (NASDAQ:LMDX)LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.Read More Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here LMDX Stock News HeadlinesApril 14, 2024 | morningstar.comLumiraDx Ltd LMDXFJanuary 31, 2024 | reuters.comLMDX.OJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.January 8, 2024 | msn.comWhy LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving PremarketJanuary 8, 2024 | investorplace.comWhy Is LumiraDx (LMDX) Stock Down 13% Today?January 5, 2024 | finance.yahoo.comLumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9thJanuary 2, 2024 | msn.comRoche (RHHBY) to Acquire LumiraDx's Point of Care TechnologyJanuary 2, 2024 | benzinga.comRoche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295MJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.January 2, 2024 | benzinga.comWhy LumiraDx Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving PremarketJanuary 2, 2024 | msn.comLumiraDx falls on agreement with Roche to sell assetsDecember 29, 2023 | reuters.comRoche to buy part of LumiraDx diagnostics platform for $295 millionDecember 29, 2023 | finanznachrichten.deLumiraDx Inc: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheDecember 29, 2023 | finance.yahoo.comRoche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platformDecember 29, 2023 | markets.businessinsider.comLumiraDx Agrees To Sell Point-of-Care Tech Platform To RocheDecember 29, 2023 | finance.yahoo.comLumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheDecember 29, 2023 | finance.yahoo.comLumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheDecember 26, 2023 | uk.finance.yahoo.comLumiraDx Limited (LMDX)See More Headlines Receive LMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/24/2023Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LMDX CUSIPN/A CIK1685428 Webwww.lumiradx.com Phone354-640-0540FaxN/AEmployees1,210Year FoundedN/APrice Target and Rating Average Stock Price Target$0.80 High Stock Price Target$0.80 Low Stock Price Target$0.80 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-447,790,000.00 Net Margins-268.45% Pretax Margin-264.58% Return on EquityN/A Return on Assets-77.91% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.23 Sales & Book Value Annual Sales$126.52 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.33) per share Price / BookN/AMiscellaneous Outstanding Shares318,546,000Free Float205,749,000Market Cap$5.10 million OptionableNot Optionable Beta1.73 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Veronique Ameye EMBA (Age 46)Esq., M.B.A., CEO & General Counsel Mr. Dorian LeBlanc CPA (Age 48)CFO & VP of Global Operations Ms. Colleen McMillenVice President of CommunicationsAndy WardNational Sales Director - UKMr. David Walton DMS (Age 69)Chief Commercial Officer Giffin DaughtridgePresident of North America Commercial Operations & Global Molecular SolutionsMelissa GarciaVP & Corporate CounselMore ExecutivesKey CompetitorsIterum TherapeuticsNASDAQ:ITRMJanOneNASDAQ:JANBullfrog AINASDAQ:BFRGVincerx PharmaNASDAQ:VINCMEI PharmaNASDAQ:MEIPView All Competitors LMDX Stock Analysis - Frequently Asked Questions How were LumiraDx's earnings last quarter? LumiraDx Limited (NASDAQ:LMDX) released its quarterly earnings data on Thursday, August, 24th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.01. The firm earned $21 million during the quarter, compared to the consensus estimate of $21.07 million. This page (NASDAQ:LMDX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LumiraDx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share LumiraDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.